We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported $4.33 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $0.69 for the same period compares to $0.60 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +6.12%. The company delivered an EPS surprise of +6.15%, with the consensus EPS estimate being $0.65.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- International Markets: $613 million versus $615.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.
Geographic Revenue- United States: $2.23 billion versus the four-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +11.1%.
Geographic Revenue- United States- COPAXONE: $69 million versus $49.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change.
Geographic Revenue- United States- BENDEKA / TREANDA: $40 million versus $38.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -29.8% change.
Geographic Revenue- United States- AUSTEDO: $435 million versus the four-analyst average estimate of $436.83 million. The reported number represents a year-over-year change of +28.3%.
Geographic Revenue- United States- Anda: $380 million versus the four-analyst average estimate of $351.57 million. The reported number represents a year-over-year change of +3.5%.
Geographic Revenue- Europe- COPAXONE: $53 million versus the four-analyst average estimate of $47.56 million. The reported number represents a year-over-year change of -3.6%.
Geographic Revenue- Europe- Respiratory products: $60 million versus the four-analyst average estimate of $57.37 million. The reported number represents a year-over-year change of -1.6%.
Geographic Revenue- International Markets- Generic products: $477 million versus the four-analyst average estimate of $497.41 million. The reported number represents a year-over-year change of +25.2%.
Geographic Revenue- International Markets- COPAXONE: $13 million versus $12.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30% change.
Geographic Revenue- United States- AJOVY: $58 million compared to the $56.34 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year.
Geographic Revenue- Europe- Generic products: $973 million versus the four-analyst average estimate of $930.59 million. The reported number represents a year-over-year change of +9.8%.
Shares of Teva Pharmaceutical Industries have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported $4.33 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $0.69 for the same period compares to $0.60 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +6.12%. The company delivered an EPS surprise of +6.15%, with the consensus EPS estimate being $0.65.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International Markets: $613 million versus $615.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.
- Geographic Revenue- United States: $2.23 billion versus the four-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +11.1%.
- Geographic Revenue- United States- COPAXONE: $69 million versus $49.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change.
- Geographic Revenue- United States- BENDEKA / TREANDA: $40 million versus $38.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -29.8% change.
- Geographic Revenue- United States- AUSTEDO: $435 million versus the four-analyst average estimate of $436.83 million. The reported number represents a year-over-year change of +28.3%.
- Geographic Revenue- United States- Anda: $380 million versus the four-analyst average estimate of $351.57 million. The reported number represents a year-over-year change of +3.5%.
- Geographic Revenue- Europe- COPAXONE: $53 million versus the four-analyst average estimate of $47.56 million. The reported number represents a year-over-year change of -3.6%.
- Geographic Revenue- Europe- Respiratory products: $60 million versus the four-analyst average estimate of $57.37 million. The reported number represents a year-over-year change of -1.6%.
- Geographic Revenue- International Markets- Generic products: $477 million versus the four-analyst average estimate of $497.41 million. The reported number represents a year-over-year change of +25.2%.
- Geographic Revenue- International Markets- COPAXONE: $13 million versus $12.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30% change.
- Geographic Revenue- United States- AJOVY: $58 million compared to the $56.34 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year.
- Geographic Revenue- Europe- Generic products: $973 million versus the four-analyst average estimate of $930.59 million. The reported number represents a year-over-year change of +9.8%.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Shares of Teva Pharmaceutical Industries have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.